Phase II Panitumumab-IRDye800 in Head & Neck Cancer

Recruiting now · Phase 2

Conditions studied: Head and Neck Cancer

In brief

The purpose of this study is to determine if panitumumab-IRDye800 is effective in identifying cancer, compared to surrounding normal tissue, and the further characterize the safety profile of this drug.

Key facts

Study ID

NCT04511078

Run by

University of Alabama at Birmingham

People needed

25

Starts

2021-04-02

Expected to finish

2030-12-31

Last updated by the study team

2025-12-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Biopsy confirmed diagnosis of squamous cell carcinoma of the head and neck
• Diagnosis of any T stage, any subsite within the head and neck that are scheduled to undergo surgical resection. Patients with recurrent disease or a new primary will be allowed.
• Planned standard of care surgery with curative intent for squamous cell carcinoma
• Male or female patients age ≥ 18 years
• Have life expectancy of more than 12 weeks
• Karnofsky performance status of at least 70% or ECOG/Zubrod level 1
• Have acceptable hematologic status, coagulation status, kidney function, and liver function including the following clinical results:
• Hemoglobin ≥ 9 gm/dL
• Absolute Neutrophil Count ≥ 1500
• White Blood Cell count > 3000/mm3
• Platelet count ≥ 100,000/mm3
• Serum creatinine ≤ 1.5 times upper reference range

You may not qualify if…

• Received an investigational drug within 30 days prior to first dose of panitumumab-IRDye800
• Had within 6 months prior to enrollment: MI, CVA, or uncontrolled CHF
• History of infusion reactions to any monoclonal antibody therapies
• Women who are pregnant or breast-feeding
• Evidence of QT prolongation on pretreatment ECG (greater than 440 ms in males or greater than 450 ms in females)
• Magnesium or potassium lower than the normal institutional values
• Patients receiving Class IA (quinidine, procanamide) or Class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents
• Patients with a history or evidence of interstitial pneumonitis or pulmonary fibrosis
• TSH > 13 micro International Units/mL

Where it is running

• University of Alabama at Birmingham — Birmingham, Alabama, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.